LRP8 and neoplasm: Once anti‐LRP8 antibodies become available, evaluations in preclinical studies will be required to determine their effects on tumor growth in TNBC patient‐derived xenograft models, alone and in combination with the standard chemotherapies currently used to treat TNBC in clinical practice.